Group 1 - The core viewpoint of the news is that He Yuan Bio has experienced fluctuations in stock price and trading volume, with a recent increase of 2.02% in its share price, reaching 80.64 CNY per share, while the total market capitalization stands at 28.829 billion CNY [1] - As of October 28, 2025, He Yuan Bio's main business involves the research, production, and sales of plant-derived human serum albumin using rice endosperm cell recombinant protein expression technology, with 75.44% of its revenue coming from recombinant human albumin [1][2] - The company has seen a significant increase in the number of shareholders, with a total of 47,100 shareholders as of October 28, representing an increase of 84,075% compared to the previous period [2] Group 2 - For the period from January to September 2025, He Yuan Bio reported operating revenue of 19.6608 million CNY, a year-on-year decrease of 8.51%, and a net profit attributable to the parent company of -121 million CNY, also a decrease of 8.44% year-on-year [2] - The stock has seen a decline of 11.48% year-to-date, with a recent 5-day increase of 2.71% and a 20-day decline of 31.60% [1] - The company operates within the pharmaceutical and biological industry, specifically in the blood products sector, and is categorized under several concepts including near-term new shares and innovative drugs [2]

资料显示，武汉禾元生物科技股份有限公司位于湖北省武汉市武汉东湖新技术开发区神墩五路268号， 成立日期2006年11月16日，上市日期2025年10月28日，公司主营业务涉及运用水稻胚乳细胞重组蛋白表 达技术平台进行植物源人血清白蛋白等产品的研发、生产及销售。主营业务收入构成为：重组人白蛋白 75.44%，其他24.56%。 11月25日，禾元生物涨0.99%，成交额3.61亿元。两融数据显示，当日禾元生物获融资买入额3415.52万 元，融资偿还6433.78万元，融资净买入-3018.27万元。截至11月25日，禾元生物融资融券余额合计3.13 亿元。 融资方面，禾元生物当日融资买入3415.52万元。当前融资余额3.13亿元，占流通市值的9.87%。 融券方面，禾元生物11月25日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元。 截至10月28日，禾元生物股东户数4.71万，较上期增加84075.00%；人均流通股869股，较上期减少 99.85%。2025年1月-9月，禾元生物实现营业收入1966.08万元，同比减少8.51%；归 ...

Core Viewpoint - He Yuan Bio's stock price has experienced a decline of 4.23% year-to-date and 8.12% over the last five trading days, with significant trading activity noted in recent sessions [1][2]. Group 1: Stock Performance - On November 14, He Yuan Bio's stock rose by 2.06%, reaching 87.25 CNY per share, with a trading volume of 95.86 million CNY and a turnover rate of 2.69% [1]. - Year-to-date, He Yuan Bio's stock has dropped by 4.23%, and it has fallen by 8.12% in the last five trading days [1]. - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent instance on November 7, where it recorded a net buy of -69.68 million CNY [1]. Group 2: Financial Performance - For the period from January to September 2025, He Yuan Bio reported a revenue of 19.66 million CNY, reflecting a year-on-year decrease of 8.51% [2]. - The company's net profit attributable to shareholders was -121 million CNY, a decline of 8.44% year-on-year [2]. Group 3: Company Overview - He Yuan Bio, established on November 16, 2006, is located in Wuhan, Hubei Province, and specializes in the research, production, and sales of products using rice endosperm cell recombinant protein expression technology [1]. - The company's main business revenue composition includes 75.44% from recombinant human albumin and 24.56% from other products [1].

Group 1 - The core viewpoint of the news is that He Yuan Bio has experienced a significant decline in stock price and financial performance, with a notable drop in trading activity and net outflow of funds [1][2]. Group 2 - As of November 12, He Yuan Bio's stock price increased by 2.33% to 88.00 CNY per share, with a trading volume of 1.16 billion CNY and a market capitalization of 31.46 billion CNY [1]. - The company has seen a net outflow of 11.32 million CNY in principal funds, with large orders showing a buy of 20.27 million CNY and a sell of 27.88 million CNY [1]. - Year-to-date, He Yuan Bio's stock price has decreased by 3.40%, and it has dropped 21.43% over the last five trading days [1]. - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent instance on November 7, where it recorded a net buy of -69.68 million CNY [1]. Group 3 - He Yuan Bio, established on November 16, 2006, is located in Wuhan, Hubei Province, and specializes in the research, production, and sales of products using rice endosperm cell recombinant protein expression technology [1]. - The company's main business revenue composition includes 75.44% from recombinant human albumin and 24.56% from other products [1]. Group 4 - He Yuan Bio belongs to the pharmaceutical and biological industry, specifically in the blood products sector, and is associated with concepts such as innovative drugs, newly listed stocks, biopharmaceuticals, and mid-cap stocks [2]. - As of October 28, the number of shareholders for He Yuan Bio reached 47,100, an increase of 84,075% compared to the previous period, while the average circulating shares per person decreased by 99.85% to 869 shares [2]. - For the period from January to September 2025, He Yuan Bio reported a revenue of 19.66 million CNY, a year-on-year decrease of 8.51%, and a net profit attributable to the parent company of -121 million CNY, also down 8.44% year-on-year [2].

Core Insights - He Yuan Bio experienced a significant decline of 8.02% in stock price on November 11, with a trading volume of 9.52 billion yuan [1] - The company reported a net financing outflow of 16.81 million yuan on the same day, with a total financing and securities balance of 403 million yuan [1] Group 1: Financial Performance - For the period from January to September 2025, He Yuan Bio achieved a revenue of 19.66 million yuan, representing a year-on-year decrease of 8.51% [2] - The net profit attributable to the parent company was -121 million yuan, reflecting a year-on-year decline of 8.44% [2] Group 2: Shareholder and Market Data - As of October 28, the number of shareholders for He Yuan Bio reached 47,100, an increase of 84,075% compared to the previous period [2] - The average number of circulating shares per shareholder decreased to 869 shares, down by 99.85% from the previous period [2] Group 3: Company Overview - He Yuan Bio, established on November 16, 2006, is located in Wuhan, Hubei Province, and specializes in the research, production, and sales of products using rice embryo cell recombinant protein expression technology [1] - The main business revenue composition includes 75.44% from recombinant human albumin and 24.56% from other products [1]

Core Viewpoint - He Yuan Bio experienced a stock price increase of 3.61% on November 3, with a trading volume of 1.603 billion yuan, indicating positive market sentiment towards the company [1]. Financing Summary - On November 3, He Yuan Bio had a financing buy-in amount of 154 million yuan, with a net financing purchase of 63.89 million yuan after repaying 90.45 million yuan [1]. - The total financing and securities balance for He Yuan Bio reached 256 million yuan, accounting for 4.87% of its circulating market value [1]. - There were no short-selling activities reported on November 3, with zero shares sold or repaid [1]. Company Overview - He Yuan Bio, established on November 16, 2006, is located in Wuhan, Hubei Province, and specializes in the research, production, and sales of products using rice endosperm cell recombinant protein expression technology [1]. - The company's main revenue source is recombinant human albumin, which constitutes 75.44% of its total revenue, while other products account for 24.56% [1]. Shareholder Information - As of October 28, He Yuan Bio had 47,100 shareholders, a significant increase of 84,075% compared to the previous period [2]. - The average number of circulating shares per shareholder decreased to 869 shares, down by 99.85% from the previous period [2]. Financial Performance - For the period from January to September 2025, He Yuan Bio reported a revenue of 19.66 million yuan, reflecting a year-on-year decrease of 8.51% [2]. - The company recorded a net profit attributable to shareholders of -121 million yuan, which is an 8.44% decrease compared to the same period last year [2].

Group 1 - The core point of the news is that He Yuan Bio experienced a significant stock price increase of 213.49% on October 28, with a trading volume of 2.782 billion yuan [1] - On the same day, He Yuan Bio had a financing buy amount of 369 million yuan, with a net financing purchase of 269 million yuan, indicating strong investor interest [1] - The company's total financing and securities balance reached 269 million yuan, accounting for 7.21% of its circulating market value [1] Group 2 - As of October 28, the number of shareholders for He Yuan Bio increased to 47,100, a rise of 84,075% compared to the previous period [2] - The average circulating shares per person decreased to 869 shares, a drop of 99.85% from the previous period [2] - For the period from January to September 2025, He Yuan Bio reported an operating income of 19.6608 million yuan, a year-on-year decrease of 8.51%, and a net profit attributable to the parent company of -121 million yuan, also a decrease of 8.44% year-on-year [2]